- Home
- CHEK vs RDHL Comparison
CHEK vs RDHL Comparison
Compare CHEK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- RDHL
- Stock Information
- Founded
- CHEK 2004
- RDHL 2009
- Country
- CHEK Israel
- RDHL Israel
- Employees
- CHEK N/A
- RDHL N/A
- Industry
- CHEK Medical Electronics
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- RDHL Health Care
- Exchange
- CHEK Nasdaq
- RDHL Nasdaq
- Market Cap
- CHEK 4.3M
- RDHL 3.8M
- IPO Year
- CHEK 2015
- RDHL N/A
- Fundamental
- Price
- CHEK $0.76
- RDHL $2.02
- Analyst Decision
- CHEK
- RDHL
- Analyst Count
- CHEK 0
- RDHL 0
- Target Price
- CHEK N/A
- RDHL N/A
- AVG Volume (30 Days)
- CHEK 29.6K
- RDHL 19.8K
- Earning Date
- CHEK 08-14-2025
- RDHL 04-10-2025
- Dividend Yield
- CHEK N/A
- RDHL N/A
- EPS Growth
- CHEK N/A
- RDHL N/A
- EPS
- CHEK N/A
- RDHL N/A
- Revenue
- CHEK N/A
- RDHL $8,042,999.00
- Revenue This Year
- CHEK N/A
- RDHL $381.91
- Revenue Next Year
- CHEK N/A
- RDHL N/A
- P/E Ratio
- CHEK N/A
- RDHL N/A
- Revenue Growth
- CHEK N/A
- RDHL 23.17
- 52 Week Low
- CHEK $0.56
- RDHL $1.71
- 52 Week High
- CHEK $3.04
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- CHEK 45.42
- RDHL 56.71
- Support Level
- CHEK $0.75
- RDHL $1.75
- Resistance Level
- CHEK $0.86
- RDHL $2.08
- Average True Range (ATR)
- CHEK 0.03
- RDHL 0.10
- MACD
- CHEK 0.00
- RDHL 0.02
- Stochastic Oscillator
- CHEK 33.11
- RDHL 82.42
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.